MIA, alongside ACEMID, hosted an important melanoma data workshop in Sydney, to prepare for the massive volumes of data that will help create the evidence for a national targeted melanoma-screening program.
La Roche-Posay, the number one skincare brand recommended by dermatologists worldwide, and MIA, world leading melanoma research organisation, have embarked on a new five-year partnership to support critical melanoma research and accelerate awareness of sun safety.
Announcing a partnership between MIA and the Boating Industry Association (BIA) to promote sun safety amongst boating enthusiasts, including MIA hosting a stand at the Sydney International Boat Show in August.
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
Our 2024 Australians of the Year recently explored the Northern Territory, as part of a visit organised by the Australia Day Council. View the photo album.
Melanoma patients throughout the Riverina will benefit from strengthened melanoma services thanks to the newly opened MIA Amie St Clair clinic in Wagga, which includes a 3D full body imaging machine, clinic rooms and space for support groups and community events.
In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers across the globe.
Congratulations to Professor Georgina Long AO, elected as a Fellow of the Australian Academy of Science in recognition of her outstanding contribution to science.
Listen to Profs Long and Scolyer on ABC Radio Sydney for an update on Richard's #braincancer journey & recent results. how melanoma science is being used to treat his #glioblastoma. Budget funding news and their Australian of the Year activities.
Last night's Federal Budget announcement included a $25 million commitment to prevention and early detection of skin cancer and melanoma, and $10.3 million has been allocated for MIA to develop an evidence-based roadmap for a targeted skin cancer screening program.
